跳转至内容
Merck
CN
所有图片(1)

文件

203695

Sigma-Aldrich

bpV(phen)

A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator.

登录查看公司和协议定价
所有图片(1)
别名:
bpV(phen), Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII
线性分子式:
K[VO(O2)2C12H8N2]
CAS号:
42494-73-5
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

100

检测方案

≥99% (51V-NMR)

形式

solid

效能

38 nM IC50

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

yellow

溶解性

water: 5 mg/mL

运输

ambient

储存温度

−20°C

InChI

1S/C12H8N2.K.2H2O2.O.V/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1;;2*1-2;;/h1-8H;;2*1-2H;;/q;+1;;;;

InChI key

MQPXOTNOFVCXDA-UHFFFAOYSA-N

一般描述

A potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
A potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM).
The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.

生化/生理作用

Cell permeable: no
Primary Target
PTEN
Product does not compete with ATP.
Reversible: no

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

重悬

Unstable in solution; reconstitute just prior to use.

其他说明

Schmid, A.C., et al. 2004. FEBS Lett.566, 35.
Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
Drake, P.G., et al. 1996. Endocrinology137, 4960.
Bevan, A.P., et al. 1995. Am. J. Physiol.268, E60.
Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
Yale, J.F., et al. 1995. Diabetes 44, 1274.
Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sameer S Chopra et al.
Cell systems, 10(1), 66-81 (2019-12-10)
Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门